BRPI0414553A - previsão do resultado de tratamento contra o cáncer de mama - Google Patents

previsão do resultado de tratamento contra o cáncer de mama

Info

Publication number
BRPI0414553A
BRPI0414553A BRPI0414553-4A BRPI0414553A BRPI0414553A BR PI0414553 A BRPI0414553 A BR PI0414553A BR PI0414553 A BRPI0414553 A BR PI0414553A BR PI0414553 A BRPI0414553 A BR PI0414553A
Authority
BR
Brazil
Prior art keywords
breast cancer
tamoxifen
response
prediction
cases
Prior art date
Application number
BRPI0414553-4A
Other languages
English (en)
Inventor
Xiao-Jun Ma
Mark G Erlander
Dennis C Sgroi
Edward Enright
Original Assignee
Arcturus Bioscience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/727,100 external-priority patent/US7504214B2/en
Priority claimed from US10/773,761 external-priority patent/US9856533B2/en
Application filed by Arcturus Bioscience Inc filed Critical Arcturus Bioscience Inc
Publication of BRPI0414553A publication Critical patent/BRPI0414553A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/40—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mechanical, radiation or invasive therapies, e.g. surgery, laser therapy, dialysis or acupuncture
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medical Informatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Primary Health Care (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Data Mining & Analysis (AREA)
  • Databases & Information Systems (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Biomedical Technology (AREA)

Abstract

"PREVISãO DO RESULTADO DE TRATAMENTO CONTRA O CáNCER DE MAMA". Métodos e composições são providos para a identificação de assinaturas de expressão em casos de câncer de mama ER+, onde as assinaturas estão correlacionadas com a resposta, ou falta da mesma, ao tratamento com tamoxifeno ou outro agente antiestrogênico contra câncer de mama. Os perfis de assinatura são identificados com base na amostragem de amostras de tecido de mama de referência a partir de casos independentes de câncer de mama e provêem um conjunto confiável de critérios moleculares para prever a eficácia de tratamento de um indivíduo com câncer de mama com tamoxifeno ou outro agente antiestrogênico contra câncer de marna. Métodos adicionais e composições são providos para prever a resposta a tamoxifeno ou outro agente antiestrogênico contra câncer de mama em casos de câncer de mama por uso de biomarcadores múltiplos. Dois biomarcadores mostram uma expressão aumentada correlacionada com a resposta a tamoxifeno enquanto dois outros biomarcadores mostram expressão diminuída correlacionada com a resposta a tamoxifeno.
BRPI0414553-4A 2003-09-19 2004-09-17 previsão do resultado de tratamento contra o cáncer de mama BRPI0414553A (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US50408703P 2003-09-19 2003-09-19
US10/727,100 US7504214B2 (en) 2003-09-19 2003-12-02 Predicting outcome with tamoxifen in breast cancer
US10/773,761 US9856533B2 (en) 2003-09-19 2004-02-06 Predicting breast cancer treatment outcome
US54719904P 2004-02-23 2004-02-23
PCT/US2004/030789 WO2005028681A1 (en) 2003-09-19 2004-09-17 Predicting breast cancer treatment outcome

Publications (1)

Publication Number Publication Date
BRPI0414553A true BRPI0414553A (pt) 2006-11-07

Family

ID=34382172

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0414553-4A BRPI0414553A (pt) 2003-09-19 2004-09-17 previsão do resultado de tratamento contra o cáncer de mama

Country Status (7)

Country Link
US (1) US20060154267A1 (pt)
EP (1) EP1670946B1 (pt)
JP (1) JP2007505630A (pt)
AU (1) AU2004274973A1 (pt)
BR (1) BRPI0414553A (pt)
CA (1) CA2539107A1 (pt)
WO (1) WO2005028681A1 (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030198972A1 (en) 2001-12-21 2003-10-23 Erlander Mark G. Grading of breast cancer
US9856533B2 (en) 2003-09-19 2018-01-02 Biotheranostics, Inc. Predicting breast cancer treatment outcome
JP2007528374A (ja) 2004-03-02 2007-10-11 セレクター，リミティド ライアビリティ カンパニー Ｄｉａｐｅｕｔｉｃ（登録商標）剤としてのリン脂質類似体、及びその方法
US8540968B2 (en) 2004-03-02 2013-09-24 Cellectar, Inc. Phospholipid ether analogs as agents for detecting and locating cancer, and methods thereof
WO2006103442A2 (en) * 2005-04-01 2006-10-05 Ncc Technology Ventures Pte. Ltd. Materials and methods relating to breast cancer classification
JP2009507496A (ja) * 2005-09-09 2009-02-26 ボード オブ リージェンツ オブ ザ ユニバーシティ オブ テキサス システム エストロゲン受容体（ｅｒ）遺伝子およびｅｒ関連遺伝子のゲノム発現の算出された指標
CN100457922C (zh) * 2005-10-20 2009-02-04 康哲医药研究(深圳)有限公司 检测酪丝亮肽抗肝癌效果的方法及所用试剂盒与基因芯片
US20090326333A1 (en) * 2005-12-09 2009-12-31 Goetz Matthew P Assessing outcomes for breast cancer patients
JP2007267700A (ja) * 2006-03-31 2007-10-18 Kochi Univ Ｈｏｘｂ１３遺伝子のメチル化を指標とする腎細胞癌を含む悪性腫瘍の判定方法
ATE545029T1 (de) * 2006-05-18 2012-02-15 Mayo Foundation Beurteilung der ergebnisse für brustkrebspatienten
EP1873258A1 (en) * 2006-06-26 2008-01-02 Universitätsklinikum Hamburg-Eppendorf Detection of ESR1 amplification in breast cancer
EP2090588A4 (en) 2006-10-23 2010-04-07 Neocodex S L IN VITRO PROCEDURE FOR THE PROGNOSIS AND / OR DIAGNOSIS OF OVER SENSITIVITY TO ESTROGENIC OR SUBSTANCES WITH ESTROGENIC EFFECT
WO2008133493A1 (en) * 2007-04-27 2008-11-06 Erasmus University Medical Center Rotterdam Prediction of responsiveness to anti-estrogen treatment in breast cancer
CA2698569A1 (en) * 2007-09-06 2009-09-03 Mark G. Erlander Tumor grading and cancer prognosis
WO2009067611A1 (en) * 2007-11-20 2009-05-28 University Of South Florida Seven gene breast cancer predictor
US10295540B1 (en) * 2009-02-13 2019-05-21 Cancer Genetics, Inc. Systems and methods for phenotypic classification using biological samples of different sample types
SI3708192T1 (sl) 2009-06-12 2023-12-29 Cellectar, Inc. Eter fosfolipidne spojine za zdravljenje raka in slikanje in detekcijo rakavih izvornih celic
GB0916124D0 (en) 2009-09-15 2009-10-28 Univ Cardiff Method and kit for the classification and prognosis of wounds
WO2011132726A1 (ja) * 2010-04-22 2011-10-27 東レ株式会社 ａＲＮＡの調製方法および遺伝子発現の解析方法
WO2012079059A2 (en) * 2010-12-09 2012-06-14 Biotheranostics, Inc. Post-treatment breast cancer prognosis
GB201021182D0 (en) 2010-12-14 2011-01-26 Univ Cardiff Methdo and kit for the classification and prognosis of chronic wounds
JP2014505257A (ja) * 2011-01-28 2014-02-27 バイオデシックス・インコーポレイテッド ホルモン療法および組み合わせ療法のための転移性乳癌患者の選択の予測試験
GB201103898D0 (en) 2011-03-08 2011-04-20 Univ Cardiff Molecular targets for healing or treating wounds
AU2012332481B2 (en) * 2011-11-04 2017-01-19 Invivis Sas Assay for predictive biomarkers of anti-estrogen efficacy
EP3044335B1 (en) 2013-09-11 2020-09-09 Bio Theranostics, Inc. Predicting breast cancer recurrence
WO2016207986A1 (ja) * 2015-06-24 2016-12-29 株式会社日立製作所 検査システム、検査装置、及び検査方法
EP3374526A4 (en) 2015-11-13 2019-09-11 Biotheranostics, Inc. INTEGRATION OF TUMOR CHARACTERISTICS WITH A BREAST CANINE INDEX
AU2016368696B2 (en) * 2015-12-07 2021-11-25 Ontario Institute For Cancer Research (Oicr) Gene signature of residual risk following endocrine treatment in early breast cancer
CN110741098A (zh) * 2017-05-29 2020-01-31 朱拉蓬基金会 预测患有肝细胞癌(hcc)或胆管癌(cca)的受试者的生存结果的方法
EP3837548A2 (en) * 2018-08-17 2021-06-23 F. Hoffmann-La Roche AG Diagnostic and therapeutic methods for the treatment of breast cancer
JP7441828B2 (ja) * 2018-09-24 2024-03-01 ホロジック， インコーポレイテッド ***マッピングおよび異常定位

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE503023T1 (de) * 2001-06-18 2011-04-15 Rosetta Inpharmatics Llc Diagnose und prognose von brustkrebspatientinnen
US7622260B2 (en) * 2001-09-05 2009-11-24 The Brigham And Women's Hospital, Inc. Diagnostic and prognostic tests
US7504214B2 (en) * 2003-09-19 2009-03-17 Biotheranostics, Inc. Predicting outcome with tamoxifen in breast cancer

Also Published As

Publication number Publication date
WO2005028681A1 (en) 2005-03-31
AU2004274973A1 (en) 2005-03-31
JP2007505630A (ja) 2007-03-15
US20060154267A1 (en) 2006-07-13
EP1670946A1 (en) 2006-06-21
EP1670946B1 (en) 2012-11-07
CA2539107A1 (en) 2005-03-31

Similar Documents

Publication Publication Date Title
BRPI0414553A (pt) previsão do resultado de tratamento contra o cáncer de mama
Huang et al. Epigenetics in breast cancer: what's new?
Cai et al. Drugging chromatin in cancer: recent advances and novel approaches
BRPI0606346A2 (pt) composição cosmeticamente aceitável e método de tratamento de um substrato selecionado entre o cabelo, a pele ou as unhas
BRPI0507463A (pt) uso de glufosfamide e gemcitabine , produto, e, combinação de glufosfamide e gemcitabine
CY1119112T1 (el) K-ras μεταλλαξεις και θεραπεια anti-egfr αντισωματος
Ying et al. Epigenetic repression of regulator of G‐protein signaling 2 by ubiquitin‐like with PHD and ring‐finger domain 1 promotes bladder cancer progression
BR0311823A (pt) Método para análise in situ de parâmetros de formação
NZ593225A (en) Gene expression markers (CMYC and Ki-67) for colorectal cancer prognosis
WO2009015050A3 (en) Gene expression profile for predicting ovarian cancer patient survival
WO2004111273A3 (en) Gene expression markers for response to egfr inhibitor drugs
BRPI0717219A2 (pt) "composição imunogênica, método para tratar ou prevenir doença, e, uso de uma composição imunogênica."
IL177346A0 (en) Compositions and methods for characterizing, regulating, diagnosing, and treating cancer
WO2006119365A3 (en) Composition and methods for cancer diagnosis utilizing the mir 17-92 cluster
CL2007003649A1 (es) Un conjugado de molecula asociado a anticuerpo monoclonal humano anti-cd70; composicion que comprende al conjugado de molecula asociado a anticuerpo; metodo de inhibicion del crecimiento de celulas tumorales que expresan cd70.
Ellinger et al. DNA hypermethylation in papillary renal cell carcinoma
BRPI1007048A2 (pt) método e kit para correlacionar os níveis relativos da quantidade de pelo menos um de her-2 ou homodímeros de her-2 em uma amostra biológica de um indivíduo, e , método para prognosticar se um indivíduo com câncer e que é tratado com um agente que atua em her-2 é provável ter um evento significante.
BR112012009262A2 (pt) ''método para inibir a proliferação de células de câncer positivo para ar em um indivíduo diagnosticado com,ou qual se suspeita que tenha cânce positivo para ar e método para identificar se um indivíduo é um candidato para tratamento com uma composiçâo
BRPI0701433A (pt) uso de uma composição cosmética, processo para melhorar a cor das fibras queratìnicas tingidas artificialmente, processo de coloração e agente de coloração multicomponente ou kit
BRPI0417903A (pt) método de melhorar a detecção de sinal de um componente de parede celular de células
SG158133A1 (en) Method for reversing multiple resistance in animal cells
CL2008001517A1 (es) Dispositivo para determinar el riesgo de progresion de melanoma que comprende oligonucleotidos de uno o mas marcadores de pronostico de melanoma (mpms) escogidos de un grupo de seleccion; procedimiento para determinar la prognosis de melanoma en un paciente; procedimiento para determinar la adecuacion de un paciente de melanoma para un ensayo de droga.
Fasching et al. HER2 and TOP2A amplification in a hospital-based cohort of breast cancer patients: associations with patient and tumor characteristics
BR112012005670A2 (pt) ''método para a identificação de um paciente com câncer que pode se beneficiar com a terapia antiagiogênica, método para a predição da responsividade de um paciente com câncer à terapia antiangiogênica, uso de um anticorpo anto- vegf para melhorar o efeito do tratamento de um paciente sofrendo de câncer, método ou uso, kit útil para realizar o método, uso de uma proteína ou usom kit útil para realizar o método, uso de uma proteína ou oligonucleotídeo ou matriz de polinecleotídeo para determinar o nível de expressão de bfgf em um método e kit ou uso
EP1404365A4 (en) METHODS AND COMPOSITIONS FOR INHIBITING, PREVENTING OR REDUCING TUMOR CELL GROWTH IN PATIENTS RESISTANT TO ANTI-NEOPLASTIC EFFECTS OF ANTI-OESTROGEN TREATMENT

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2112 DE 28/06/2011.